Gynecologic cancer intergroup (GCIG) consensus review for uterine and ovarian carcinosarcoma

International Journal of Gynecological Cancer

Volumn 24, Issue 9, 2014, Pages S55-S60

  Berton Rigaud, Dominique ^a   Devouassoux Shisheboran, Mojgan ^b   Ledermann, Jonathan A ^c   Leitao, Mario M ^d   Powell, Matthew A ^e   Poveda, Andres ^f   Beale, Philip ^g   Glasspool, Rosalind M ^h   Creutzberg, Carien L ⁱ   Harter, Philipp ^j   Kim, Jae Weon ^k   Reed, Nicholas Simon ^h   Ray Coquard, Isabelle ^l  

^a CENTRE RENÉ GAUDUCHEAU   (France)

^b CROIX ROUSSE HOSPITAL   (France)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^g Sydney Local Health District   (Australia)

^h BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

ⁱ LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^j KLINIKEN ESSEN MITTE   (Germany)

^k Seoul National University College of Medicine   (South Korea)

^l CENTRE LÉON BÉRARD   (France)

more..

Author keywords

Gynecological carcinosarcomas; Metastatic disease; Molecular analysis; Primary treatment; Rare tumor

Indexed keywords

ADJUVANT CHEMOTHERAPY; ADJUVANT RADIOTHERAPY; ADVANCED CANCER; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CARCINOSARCOMA; CLINICAL FEATURE; METASTASIS; MOLECULAR GENETICS; OVARIAN CARCINOSARCOMA; PRIORITY JOURNAL; REVIEW; UTERINE CARCINOSARCOMA; UTERUS SURGERY; CONSENSUS; FEMALE; HUMAN; MEDICAL SOCIETY; MULTIMODALITY CANCER THERAPY; ONCOLOGY; OVARIAN NEOPLASMS; PATHOLOGY; PRACTICE GUIDELINE; UTERINE NEOPLASMS;

CARCINOSARCOMA; COMBINED MODALITY THERAPY; CONSENSUS; FEMALE; HUMANS; MEDICAL ONCOLOGY; OVARIAN NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; SOCIETIES, MEDICAL; UTERINE NEOPLASMS;

EID: 84923136396     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0000000000000228     Document Type: Review

References (35)

1. Amant F, Cadron I, Fuso L, et al. Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer. Gynecol Oncol. 2005;98:274-280.
2. FIGO staging for carcinoma of the vulva, cervix, and corpus uteri. Int J Gynaecol Obstet. 2014;125:97-98.
3. D'Angelo E, Prat J. Pathology of mixed Müllerian tumours. Best Pract Res Clin Obstet Gynaecol. 2011;25:705-718.
4. Sreenan JJ, Hart WR. Carcinosarcomas of the female tract. A pathological study of 29 metastatic tumors: further evidence for the dominant role of the epithelial component and the conversion theory of histogenesis. Am J Surg Pathol. 1995;19:666-674.
5. Gorai I, Yanagibashi T, Taki A, et al. Uterine carcinosarcoma is derived from a single stem cell: an in vitro study. Int J Cancer. 1997;72:821-827.
6. Fujii H, Yoshida M, Gong ZX, et al. Frequent genetic heterogeneity in the clonal evolution of gynecological carcinosarcoma and its influence on phenotypic diversity. Cancer Res. 2000;60:114-120.
7. Amant F, Vloeberghs V, Woestenborghs H, et al. Transition of epithelial toward mesenchymal differentiation during ovarian carcinosarcoma tumorigenesis. Gynecol Oncol. 2003;90: 372-377.
8. Murray S, Linardou H, Mountzios G, et al. Low frequency of somatic mutations in uterine sarcomas: a molecular analysis and review of the literature. Mutat Res. 2010;686:68-73.
9. De Jong RA, Nijman HW, Wilbrandi TF, et al. Molecular markers and clinical behavior of uterine carcinosarcomas: focus on the epithelial component. Mol Pathol. 2011;24:1368-1379.
10. Growdon W, Roussel B, Scialabba V, et al. Tissue-specific signatures of activating PI3CA and RAS mutations in carcinosarcomas of gynecologic origin. Gynecol Oncol. 2011;121:212-217.
11. Cimbaluk D, Rotmensch J, Scudiere J, et al. Uterine carcinosarcoma: immunohistochemical studies on tissue microarrays with focus on potential therapeutic targets Gynecol Oncol. 2007;105:138-144.
12. Garg G, Shah J, Kumar S, et al. Ovarian and uterine carcinosarcomas: a comparative analysis of prognostic variables and survival outcomes. Int J Gynecol Cancer. 2010;20:888-894.
13. Ferguson SE, Tornos C, Hummer A, et al. Prognostic features of surgical stage I uterine carcinosarcoma. Am J Surg Pathol. 2007;31:1653-1661.
14. Rauh-Hain JA, Growdon WB, Rodriguez N, et al. Carcinosarcoma of the ovary: a case-control study. Gynecol Oncol. 2011;121:477-481.
15. Nemani D, Mitra N, Guo M, et al. Assessing the effects of lymphadencectomy and radiation therapy in patients with uterine carcinosarcoma: a SEER analysis. Gynecol Oncol. 2008;111:82-88.
16. Vorgias G, Fotiou S. The role of lymphadenectomy in uterine carcinomas (malignant mixed Müllerian tumours): a critical literature review. Arch Gynecol Obstet. 2010;282:659-664.
17. Reed NS, Mangioni C, Malmstrom H, et al. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer. 2008;44:808-818. [Erratum appears in Eur J Cancer. 2008;44:1612].
18. Wright JD, Seshan VE, Shah M, et al. The role of radiation in improving survival for early-stage carcinosarcoma and leiomyosarcoma. Am J Obstet Gynecol. 2008;199:531-538.
19. Clayton Smith D, Kenneth Macdonald O, Gaffney DK, et al. The impact of adjuvant radiation therapy on survival in women with uterine carcinosarcoma. Radiother Oncol. 2008;88:227-232.
20. Wolfson AH, Brady MF, Rocereto T, et al. A Gynecologic Oncology Group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. Gynecol Oncol. 2007;107:177-185.
21. Omura GA, Major FJ, Blessing JA, et al. A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas. Cancer. 1983;52:626-632.
22. Pautier P, Floquet A, Gladieff L, et al. A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). Ann Oncol. 2013;24:1099-1104.
23. Sutton G, Kauderer J, Carson LF, et al. Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol. 2005;96:630-634.
24. Powell MA, Filiaci VL, Rose PG, et al. Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group Study. J Clin Oncol. 2010;28:2727-2731.
25. Duska LR, Garett A, Eltabbakh MD, et al. Paclitaxel and platinum chemotherapy for malignant mixed Müllerian tumors of the ovary. Gynecol Oncol. 2002;85:459-463.
26. Shylasree TS, Bryant A, Athavale R. Chemotherapy and/or radiotherapy in combination with surgery for ovarian carcinosarcoma. Cochrane Database Syst Rev. 2013;2:CD006246.
27. Makker V, Abu-Rustum NR, Alektiar KM, et al. A retrospective assessment of outcomes of chemotherapy-based versus radiation-only adjuvant treatment for completely resected stage I-IV uterine carcinosarcoma. Gynecol Oncol. 2008;111: 249-254.
28. NCCN Guidelines Version 3.2012- Endometrial carcinoma http://www.nccn.org/professionals/physician-gls/pdf/ uterine.pdf (Accessed on September 19, 2012).
29. Sutton G, Brunetto VL, Kilgore L, et al. Trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol. 2000;79:147-153.
30. Morrow CP, Bundy BN, Hoffman J, et al. Adriamycin chemotherapy for malignant mixed mesodermal tumor of the ovary. a Gynecologic Oncology Group Study. Am J Clin Oncol. 1986;9:24-26.
31. Pectasides D, Pectasides E, Papaxoinis G, et al. Combination chemotherapy with carboplatin, paclitaxel and pegylated liposomal doxorubicin for advanced or recurrent carcinosarcoma of the uterus: clinical experience of a single institution. Gynecol Oncol. 2008;110:299-303.
32. Homesley HD, Filiaci V, Markman M, et al. Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25:526-531.
33. Galaal K, van der Heijden E, Godfrey K, et al. Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma. Cochrane Database Syst Rev. 2013;2:CD006812.
34. Hoskins PI, Le N, Ellard S, et al. Carboplatin plus paclitaxel for advanced or recurrent uterine malignant mixed Müllerian tumors. The British Columbia Cancer Agency experience. Gynecol Oncol. 2008;108:58-62.
35. Huh WK, Sill MW, Darcy KM, et al. Efficacy and safety of imatinib mesylate (Gleevec\) and immunohistochemical expression of c-Kit and PDGFR-A in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus. Gynecol Oncol. 2010;117:248-254.